Genome Editing Market Industry Size , Share, Trends, Revenue Growth And Forecast To 2024| Grand View Research, Inc
“The global genome editing market size was valued at USD 2.25 billion in 2015 .�
The global genome editing market is anticipated to reach USD 8.1 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers attributing to the expansion include early applications of DNA editing to therapeutics. Use of the technology for the disease eradication through direct correction of disturbances in normal physiology, engineering the immune response, and alteration of pathogen targets in the host is anticipated to drive the market with substantial opportunities. The ability of genome editing therapies to offer a significant improvement over current treatment options is important in enabling editing technologies to capture significant revenue share. Improved efficacy, reduced side effects, and the potential for cure for specific diseases, can be attributed to induce growth in the coming years. Moreover, technological advancements with respect to the development of novel vectors for delivery is anticipated to fuel growth in the coming years. Rising competition amongst the operating entities in order to gain the larger share of revenue is also responsible for the projected growth. These companies leverage industry collaborations for the acceleration of diversified product pipelines. Browse Details of Report @ www.grandviewresearch.com/industry-analysis/genome-editing-market
Follow Us:
Further Key Findings from the Report Suggest: There has been great excitement surrounding the highly adaptable CRISPR technology.
The increased ease of retargeting and the ability to multiplex goes a long way toward explaining the speed with which CRISPR-centric companies have sprung up. Ex-vivo mode of delivery accounted for the largest share of the revenue.
Therapy through ex-vivo mode of delivery allow the control over the specific dosage of therapeutic molecules delivered to cells.
Cell line engineering dominated with respect to revenue generation owing to the high utilization of technology in stem cell engineering.
There is comparatively, higher adoption of the technology in the biotechnology and pharmaceutical organizations for the purpose of therapeutic development.
Availability of other services such as gRNA library production and screening service along with editing is anticipated to propel growth in the outsourcing services.
Asia Pacific is anticipated to witness fastest growth over the forecast period owing to rising penetration of technology in comparatively immature market.
Key players contributing in this market are Thermo Fisher Scientific, Inc., Sangamo, Editas Medicine, Recombinetics, Inc, Sigma Aldrich Corporation, CRISPR THERAPEUTICS, Intellia Therapeutics, Inc., Caribou Biosciences, Inc.
These participants are capitalizing on unique advantages offered by the nuclease technology, they are working on.
Grand View Research has segmented the molecular scissors/genome editing market on the basis of technology, delivery method, application, end-use, service, and region: Molecular Scissors/Genome Editing Technology Outlook (Revenue, USD Million, 2014 - 2025) (CRISPR)/Cas9
TALENs/MegaTALs
ZFN
Others
Molecular Scissors/Genome Editing Delivery Method Outlook (Revenue, USD Million, 2014 - 2025) Ex-Vivo
In-Vivo
Molecular Scissors/Genome Editing Application Outlook (Revenue, USD Million, 2014 - 2025) Cell Line Engineering
Animal Genetic Engineering
Plant Genetic Engineering
Other Applications
Molecular Scissors/Genome Editing End-use Outlook (Revenue, USD Million, 2014 - 2025)
Follow Us:
Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations
Molecular Scissors/Genome Editing Service Outlook (Revenue, USD Million, 2014 - 2025) Contract
In-house
Molecular Scissors/Genome Editing Service Outlook (Revenue, USD Million, 2014 - 2025) North America
o
U.S.
o
Canada
Europe o
Germany
o
UK
Asia Pacific o
Japan
o
China
Latin America o
Brazil
Middle East and Africa (MEA) o
South Africa
Browse Related Category Reports @ www.grandviewresearch.com/industry/biotechnology Table of Content of Genome Editing Market Chapter 1 Research Methodology 1.1 Information Procurement 1.2 Data Analysis Chapter 2 Executive Summary Chapter 3 Genome Editing Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market Driver Analysis 3.1.1.1 Success in pre-clinical models drives demands for genome editing therapeutics 3.1.1.2 Rising competition amongst market participants for business development
Follow Us:
3.1.1.3 Easy editing solutions for development of therapeutics for broad range of diseases 3.1.1.4 Increasing demand for synthetic genes and genetically modified organisms 3.1.1.5 Technological advancements in gene editing technologies 3.1.1.6 Rising adoption in agricultural biotechnology 3.1.2 Market Restraint Analysis 3.1.2.1 Challenges with respect to clinical translation 3.1.2.2 Regulatory, scientific, and ethical challenges pertaining to the use of gene modified products 3.1.2.3 Off-target effects of CRISPR technology 3.2 Penetration & Growth Prospect Mapping for Technology, 2015 3.3 Molecular scissors / genome editing -Swot Analysis, By Factor (Political & Legal, Economic And Technological) 3.4 Industry Analysis - Porter’s 3.5 Molecular Scissors / Genome Editing Technologies: Pipeline Analysis 3.5.1 Sangamo 3.5.2 Cellectis 3.5.3 Calyxt 3.5.4 bluebird bio 3.5.5 Editas Medicine 3.5.6 Intellia Therapeutics, Inc. 3.5.7 CRISPR THERAPEUTICS 3.5.8 Precision Biosciences 3.5.9 Precision Biosciences (Non medical domain) 3.5.10 Caribou Biosciences 3.5.11 Cibus 3.5.12 Recombinetics, Inc 3.6 Intellectual Property 3.7 Regulatory Issues 3.7.1 Orphan diseases 3.7.2 Germline editing 3.7.3 Safety issues Chapter 4 Genome Editing Market: Technology Estimates & Trend Analysis 4.1 Molecular Scissors/ Genome Editing Market: Technology Movement Analysis
Follow Us:
4.2 Molecular Scissors / Genome Editing Technology Comparison 4.3 (CRISPR)/Cas9 4.3.1 Global (CRISPR)/Cas9 market, 2014 - 2025 (USD Million) 4.4 TALENs/MegaTALs 4.4.1 Global TALENs/MegaTALs market, 2014 - 2025 (USD Million) 4.5 ZFN 4.5.1 Global ZFN market, 2014 - 2025 (USD Million) 4.6 Other Technologies 4.6.1 Global other technologies market, 2014 - 2025 (USD Million) Chapter 5 Genome Editing Market: Delivery Method Estimates & Trend Analysis 5.1 Molecular Scissors/ Genome Editing Market: Delivery Method Movement Analysis 5.1.1 Comparison of Delivery Methods 5.1.1.1 Viral delivery 5.1.1.1.1 AAV (Adeno Associated Virus). 5.1.1.1.2 IDLV (Integrase Deficient Lentivirus). 5.1.1.2 Non-viral delivery 5.1.1.2.1 Lipid Mediated 5.1.1.2.2 Electroporation 5.2 Ex-vivo 5.2.1 Global ex-vivo delivery market, 2014 - 2025 (USD Million) 5.3 In-vivo 5.3.1 Global in-vivo delivery market, 2014 - 2025 (USD Million) Chapter 6 Genome Editing Market: Application Estimates & Trend Analysis 6.1 Molecular Scissors / Genome Editing Market: Application Movement Analysis 6.2 Cell Line Engineering 6.2.1 Global cell line engineering market, 2014 - 2025 (USD Million) 6.3 Animal Genetic Engineering 6.3.1 Global animal genetic engineering market, 2014 - 2025 (USD Million) 6.4 Plant Genetic Engineering 6.4.1 Global plant genetic engineering market, 2014 - 2025 (USD Million) 6.5 Others 6.5.1 Global other applications market, 2014 - 2025 (USD Million)
Follow Us:
Chapter 7 Genome Editing Market: End-use Estimates & Trend Analysis 7.1 Molecular Scissors / Genome Editing Market: End-use Movement Analysis 7.2 Biotechnology & Pharmaceutical Companies 7.2.1 Global biotechnology & pharmaceutical companies market, 2014 - 2025 (USD Million) 7.3 Academic & Government Research Institutes 7.3.1 Global academic & government research institutes market, 2014 - 2025 (USD Million) 7.4 Contract Research Organizations (CROs) 7.4.1 Global CROs market, 2014 - 2025 (USD Million) Chapter 8 Genome Editing Market: Service Estimates & Trend Analysis 8.1 Molecular scissors / genome editing Market: Service Movement Analysis 8.2 In-house 8.2.1 Global in-house gene editing market, 2014 - 2025 (USD Million) 8.3 Contract 8.3.1 Global contract gene editing services market, 2014 - 2025 (USD Million) Chapter 9 Genome Editing Market: Regional Estimates & Trend Analysis, by Technology, Delivery Method, Application, End-use, & Service 9.1 Molecular Scissors / Genome Editing Market Share By Region, 2015 & 2025 9.2 North America 9.2.1 North America molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.2.2 U.S. 9.2.2.1 U.S molecular scissors / genome editing culture market, 2014 - 2025 (USD Million) 9.2.3 Canada 9.2.3.1 Canada molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.3 Europe 9.3.1 Europe molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.3.2 Germany 9.3.2.1 Germany molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.3.3 UK 9.3.3.1 UK molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.4 Asia Pacific 9.4.1 Asia Pacific molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.4.2 Japan
Follow Us:
9.4.2.1 Japan molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.4.3 China 9.4.3.1 China molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.5 Latin America 9.5.1 Latin America molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.5.2 Brazil 9.5.2.1 Brazil molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.6 Middle East & Africa 9.6.1 Middle East & Africa molecular scissors / genome editing market, 2014 - 2025 (USD Million) 9.6.2 South Africa 9.6.2.1 South Africa molecular scissors / genome editing market, 2014 - 2025 (USD Million) Chapter 10 Competitive Landscape 10.1 Strategy Framework 10.1.1 Genome editing companies are developing products in a range of markets 10.1.2 Genome Editing Companies are targeting a variety of markets of various sizes 10.2 Market Participation Categorization 10.3 Company Profiles 10.3.1 Merck KGaA 10.3.1.1 Company overview 10.3.1.1.1 Sigma-Aldrich Co. LLC 10.3.1.2 Financial performance 10.3.1.2.1 Financial performance 10.3.1.3 Product benchmarking 10.3.1.4 Strategic initiatives 10.3.2 Cibus 10.3.2.1 Company overview 10.3.2.1.1 Nucelis 10.3.2.2 Financial performance 10.3.2.2.1 Financial performance 10.3.2.3 Product benchmarking 10.3.2.4 Strategic initiatives 10.3.3 Recombinetics, Inc
Follow Us:
10.3.3.1 Company overview 10.3.3.2 Financial performance 10.3.3.3 Product benchmarking 10.3.3.4 Strategic initiatives 10.3.4 Sangamo 10.3.4.1 Company overview 10.3.4.2 Financial performance 10.3.4.3 Product benchmarking 10.3.4.4 Strategic initiatives 10.3.5 Editas Medicine 10.3.5.1 Company overview 10.3.5.2 Financial performance 10.3.5.3 Product benchmarking 10.3.5.4 Strategic initiatives 10.3.6 Precision Biosciences 10.3.6.1 Company overview 10.3.6.2 Financial performance 10.3.6.3 Product benchmarking 10.3.6.4 Strategic initiatives 10.3.7 CRISPR THERAPEUTICS 10.3.7.1 Company overview 10.3.7.2 Financial performance 10.3.7.3 Product benchmarking 10.3.7.4 Strategic initiatives 10.3.8 Intellia Therapeutics, Inc. 10.3.8.1 Company overview 10.3.8.2 Financial performance 10.3.8.3 Product benchmarking 10.3.8.4 Strategic initiatives 10.3.9 Caribou Biosciences, Inc 10.3.9.1 Company overview 10.3.9.2 Financial performance
Follow Us:
10.3.9.3 Product benchmarking 10.3.9.4 Strategic initiatives 10.3.10 Cellectis 10.3.10.1 Company overview 10.3.10.1.1 Calyxt 10.3.10.2 Financial performance 10.3.10.2.1 Financial performance (Calyxt) 10.3.10.3 Product benchmarking 10.3.10.4 Strategic initiatives 10.3.11 AstraZeneca 10.3.11.1 Company overview 10.3.11.2 Financial performance 10.3.11.3 Product benchmarking 10.3.11.4 Strategic initiatives 10.3.12 Takara Bio USA 10.3.12.1 Company overview 10.3.12.2 Financial performance 10.3.12.3 Product benchmarking 10.3.12.4 Strategic initiatives 10.3.13 Horizon Discovery Group plc 10.3.13.1 Company overview 10.3.13.2 Financial performance 10.3.13.3 Product benchmarking 10.3.13.4 Strategic initiatives 10.3.14 Integrated DNA Technologies, Inc. 10.3.14.1 Company overview 10.3.14.2 Financial performance 10.3.14.3 Product benchmarking 10.3.15 Egenesis Inc. 10.3.15.1 Company overview 10.3.15.2 Financial performance 10.3.15.3 Product benchmarking
Follow Us:
10.3.16 GenScript 10.3.16.1 Company overview 10.3.16.2 Financial performance 10.3.16.3 Product benchmarking 10.3.16.4 Strategic initiatives 10.3.17 New England Biolabs 10.3.17.1 Company overview 10.3.17.2 Financial performance 10.3.17.3 Product benchmarking 10.3.17.4 Strategic initiatives 10.3.18 OriGene Technologies, Inc. 10.3.18.1 Company overview 10.3.18.2 Financial performance 10.3.18.3 Product benchmarking 10.3.18.4 Strategic initiatives 10.3.19 bluebird bio, Inc. 10.3.19.1 Company overview 10.3.19.1.1 Precision Genome Engineering, Inc. (Pregenen) 10.3.19.2 Financial performance 10.3.19.2.1 Financial performance 10.3.19.3 Product benchmarking 10.3.19.4 Strategic initiatives 10.3.20 Lonza 10.3.20.1 Company overview 10.3.20.2 Financial performance 10.3.20.3 Product benchmarking 10.3.20.4 Strategic initiatives 10.3.21 Thermo Fisher Scientific, Inc. 10.3.21.1 Company overview 10.3.21.2 Financial performance 10.3.21.3 Product benchmarking 10.3.21.4 Strategic initiatives
Follow Us:
About Us: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com
Follow Us:
Follow Us: